Shire PLC (NASDAQ: SHPG) has recently received a number of price target changes and ratings updates:

  • 8/9/2017 – Shire PLC had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $206.00 price target on the stock, down previously from $216.00.
  • 8/8/2017 – Shire PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry.”
  • 8/5/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/4/2017 – Shire PLC was given a new $213.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/26/2017 – Shire PLC was given a new $159.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 7/19/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/17/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $242.00 price target on the stock.
  • 7/17/2017 – Shire PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters.”
  • 7/13/2017 – Shire PLC had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $210.00 price target on the stock.
  • 7/12/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $245.00 price target on the stock.
  • 7/11/2017 – Shire PLC was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/6/2017 – Shire PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/6/2017 – Shire PLC was upgraded by analysts at HSBC Holdings plc from a “reduce” rating to a “hold” rating.
  • 7/1/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/1/2017 – Shire PLC was given a new $222.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/23/2017 – Shire PLC was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/16/2017 – Shire PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 6/16/2017 – Shire PLC is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $222.00 price target on the stock.

Shares of Shire PLC (SHPG) opened at 149.97 on Friday. The stock has a 50 day moving average of $164.82 and a 200-day moving average of $172.65. The company has a market capitalization of $44.67 billion, a price-to-earnings ratio of 67.10 and a beta of 1.60. Shire PLC has a 1-year low of $149.75 and a 1-year high of $209.22.

Shire PLC (NASDAQ:SHPG) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.53 by $0.20. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company had revenue of $3.75 billion for the quarter. During the same period in the previous year, the firm earned $3.38 earnings per share. The firm’s quarterly revenue was up 54.2% compared to the same quarter last year. Analysts forecast that Shire PLC will post $14.93 earnings per share for the current year.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.